Toujeo is the next generation, longer-acting version of Lantus (insulin glargine ... at a discount of 15-20 per cent to Sanofi's brand price. Biosimilars are expected in Western Europe shortly ...

Novo Nordisk has warned it may have to drop prices of its insulin products in the US next year, facing pressure as rival Sanofi cuts prices of its mainstay Lantus due to biosimilar competition.

Sanofi India is divesting its insulin brand, Lantus, with Glenmark, Dr. Reddy's, and Emcure Pharma considering acquisition, ...

Business Insider reached out to the three main insulin makers for comment, and two responded: "Every health care system is unique. In Canada, the government caps prices at very low levels ...

This includes Admelog, Lantus, Toujeo ... of the nation’s top manufacturers of insulin and other diabetes medications, ...